Affiliation:
1. Laboratory of Pharmacology-Toxicology, Faculty of Medicine and Pharmacy of Casablanca, Hassan II University of
Casablanca, Casablanca, Morocco
Abstract
Aim:
The prenyl-binding protein, phosphodiesterase-δ (PDEδ), is essential for the localization
of prenylated KRas to the plasma membrane for its signaling in cancer.
Introduction:
The general objective of this work was to develop virtually new potential inhibitors of
the PDEδ protein that prevent Ras enrichment at the plasma membrane.
Methods:
All computational molecular modeling studies were performed by Molecular Operating Environment
(MOE). In this study, sixteen crystal structures of PDEδ in complex with fifteen different
fragment inhibitors were used in the protein-ligand interaction fingerprints (PLIF) study to identify the
chemical features responsible for the inhibition of the PDEδ protein. Based on these chemical characteristics,
a pharmacophore with representative characteristics was obtained for screening the BindingDB
database. Compounds that matched the pharmacophore model were filtered by the Lipinski filter.
The ADMET properties of the compounds that passed the Lipinski filter were predicted by the
Swiss ADME webserver and by the ProTox-II-Prediction of Toxicity of Chemicals web server. The
selected compounds were subjected to a molecular docking study.
Results:
In the PLIF study, it was shown that the fifteen inhibitors formed interactions with residues
Met20, Trp32, Ile53, Cys56, Lys57, Arg61, Gln78, Val80, Glu88, Ile109, Ala11, Met117, Met118,
Ile129, Thr131, and Tyr149 of the prenyl-binding pocket of PDEδ. Based on these chemical features,
a pharmacophore with representative characteristics was composed of three bond acceptors, two hydrophobic
elements, and one hydrogen bond donor. When the pharmacophore model was used in the
virtual screening of the Binding DB database, 2532 compounds were selected. Then, the 2532 compounds
were screened by the Lipinski rule filter. Among the 2532 compounds, two compounds met
the Lipinski's rule. Subsequently, a comparison of the ADMET properties and the drug properties of
the two compounds was performed. Finally, compound 2 was selected for molecular docking analysis
and as a potential inhibitor against PDEδ.
Conclusion:
The hit found by the combination of structure-based pharmacophore generation, pharmacophore-
based virtual screening, and molecular docking showed interaction with key amino acids in
the hydrophobic pocket of PDEδ, leading to the discovery of a novel scaffold as a potential inhibitor
of PDEδ.
Publisher
Bentham Science Publishers Ltd.
Reference20 articles.
1. Bos J.L.; ras oncogenes in human cancer: A review. Cancer Res 1989,49(17),4682-4689
2. Liu P.; Wang Y.; Li X.; Targeting the untargetable KRAS in cancer therapy. Acta Pharm Sin B 2019,9(5),871-879
3. Abrams S.I.; Hand P.H.; Tsang K.Y.; Mutant ras epitopes as targets for cancer vaccines. Semin Oncol 1996,23(1),118-134
4. Nussinov R.; Tsai C.J.; Jang H.; Does ras activate raf and PI3K allosterically? Front Oncol 2019,9(November),1231
5. Ahearn I.; Zhou M.; Philips M.R.; Posttranslational modifications of RAS proteins. Cold Spring Harb Perspect Med 2018,8(11),a031484
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献